Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-23
2010-11-02
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S277000
Reexamination Certificate
active
07825135
ABSTRACT:
The present invention is directed to pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
REFERENCES:
patent: 6664273 (2003-12-01), Burnett et al.
patent: 2003/0013720 (2003-01-01), Hobbs et al.
patent: 2006/0276655 (2006-12-01), Blackaby et al.
patent: 2007/0105902 (2007-05-01), Lindsley et al.
patent: 2007/0249606 (2007-10-01), Lindsley et al.
patent: 2008/0021010 (2008-01-01), Lindsley et al.
patent: 2008/0090796 (2008-04-01), Blackaby et al.
patent: 2008/0108663 (2008-05-01), Lindsley et al.
patent: WO 00/25786 (2000-05-01), None
Wermuth (The Practice of Medicinal Chemistry, Academic Press, 1996, Chapter 13, pp. 203-238.
Rogers et al (Brain Res, 493:41-50, 1989).
Williams et al (Foye's Principles of Medicinal Chemistry, 5th Ed., 2002).
Patani et al (Chem Rev 96:3147-3176, 1996).
Wermuth C.G. The Practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pp. 211-213.
Copending U.S. Appl. No. 11/922,074, filed Jun. 13, 2006, U.S. National Stage Entry of PCT/GB06/002156, published as WO 2006/134341.
Copending U.S. Appl. No. 11/991,727, filed Sep. 25, 2006, U.S. National Stage Entry of PCT/GB06/036989, published as WO 2007/041025.
Copending U.S. Appl. No. 12/084,027, filed Oct. 27, 2006, U.S. National Stage Entry of PCT/GB06/041699, published as WO 2007/053400.
Copending U.S. Appl. No. 12/085,340, filed Nov. 23, 2006, U.S. National Stage Entry of PCT/GB06/050411, published as WO 2007/060484.
Zhao et al., Bioorganic & Medicinal Chemistry Letters, 19 (2009) 1488-1491.
Lindsley et al., ChemMedChem 2006, 1, 807-811.
Blackaby Wesley
Duggan Mark E.
Hallett David
Hartman George D.
Jennings Andrew S.
Devlin Gereard
Fetterolf Brandon J
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Limited
Ricci Craig
LandOfFree
Heteroaryl piperidine glycine transporter inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl piperidine glycine transporter inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl piperidine glycine transporter inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4216153